|
55
|
196
|
5lf4J |
Human 20s proteasome complex with delanzomib at 2.0 angstrom |
|
59
|
195
|
5l66J |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with bortezomib |
|
62
|
220
|
5lf0H |
Human 20s proteasome complex with epoxomicin at 2.4 angstrom |
|
67
|
250
|
5l54A |
Yeast 20s proteasome in complex with epoxyketone inhibitor 16 |
|
70
|
244
|
5l5sB |
Yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with pr-924 |
|
71
|
244
|
5l5wB |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) |
|
57
|
204
|
5lajI |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
67
|
213
|
5lf6L |
Human 20s proteasome complex with z-lly-ketoaldehyde at 2.1 angstrom |
|
59
|
195
|
5l5rJ |
Yeast 20s proteasome with human beta5i (1-138;v31m) and human beta6 (97-111; 118-133) |
|
58
|
195
|
5l61J |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (99-132) in complex with epoxyketone inhibitor 14 |
|
58
|
196
|
5l69N |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 |
|
60
|
222
|
5l5pL |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
|
61
|
195
|
5lajJ |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
55
|
204
|
5leyI |
Human 20s proteasome complex with oprozomib at 1.9 angstrom |
|
62
|
211
|
5l5jK |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 |
|
58
|
204
|
5l60I |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with pr-924 |
|
64
|
211
|
5m2bK |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with thiazole based inhibitor ro19 |
|
60
|
234
|
5lf6E |
Human 20s proteasome complex with z-lly-ketoaldehyde at 2.1 angstrom |
|
67
|
250
|
5l55A |
Yeast 20s proteasome in complex with epoxyketone inhibitor 18 |
|
69
|
242
|
5l5tD |
Yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 |
|
69
|
240
|
5l66C |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with bortezomib |
|
62
|
233
|
5lf1D |
Human 20s proteasome complex with dihydroeponemycin at 2.0 angstrom |
|
59
|
222
|
5l5rL |
Yeast 20s proteasome with human beta5i (1-138;v31m) and human beta6 (97-111; 118-133) |
|
71
|
243
|
5l63F |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
|
64
|
241
|
5l5rG |
Yeast 20s proteasome with human beta5i (1-138;v31m) and human beta6 (97-111; 118-133) |
|
69
|
250
|
5laiA |
Ligand-induced aziridine-formation at the yeast proteasomal subunit beta5 by sulfonate esters |
|
64
|
234
|
5lf3E |
Human 20s proteasome complex with bortezomib at 2.1 angstrom |
|
69
|
228
|
5lajM |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
58
|
202
|
5lf0N |
Human 20s proteasome complex with epoxomicin at 2.4 angstrom |
|
69
|
244
|
5l5eB |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib |
|
60
|
196
|
5l5yN |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib |
|
70
|
233
|
5laiM |
Ligand-induced aziridine-formation at the yeast proteasomal subunit beta5 by sulfonate esters |
|
60
|
222
|
5l5zL |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with bortezomib |
|
63
|
231
|
5lttE |
Yeast 20s proteasome with human beta5i (1-138; r57t)in complex with pr-924 |
|
59
|
195
|
5l5dJ |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with onx 0914 |
|
67
|
233
|
5l5tM |
Yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 |
|
59
|
196
|
5l5sN |
Yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with pr-924 |
|
70
|
244
|
5l55B |
Yeast 20s proteasome in complex with epoxyketone inhibitor 18 |
|
66
|
240
|
5l5tC |
Yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 |
|
67
|
211
|
5l63K |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
|
64
|
244
|
5lexG |
Native human 20s proteasome in mg-acetate at 2.2 angstrom |
|
69
|
242
|
5l5jD |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 |
|
70
|
244
|
5l6bB |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with onx 0914 |
|
59
|
196
|
5lajN |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
61
|
226
|
5l5rH |
Yeast 20s proteasome with human beta5i (1-138;v31m) and human beta6 (97-111; 118-133) |
|
71
|
243
|
5laiF |
Ligand-induced aziridine-formation at the yeast proteasomal subunit beta5 by sulfonate esters |
|
56
|
204
|
5lf3I |
Human 20s proteasome complex with bortezomib at 2.1 angstrom |
|
65
|
241
|
5l5jG |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 |
|
64
|
241
|
5l6aG |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
|
70
|
243
|
5l6cF |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 |
